Preferred Label : lonafarnib;

MeSH note : inhibitor of farnesyl protein transferase; structure in first source;

CISMeF synonym : SCH66336;

MeSH synonym : 4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide; 1-piperidinecarboxamide, 4(2-(4-(11R-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo(5,6)cyclohepta(1,2-b)pyridine-11-yl)-1-piperidinyl)-2-oxoethyl)-; ( )4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-yl)-1-piperidinyl)-2-oxoethyl)-1-piperidinecarboxamide;

MeSH hyponym : SCH 66336; SCH-66336;

MeSH CAS label : 1-Piperidinecarboxamide, 4(2-(4-(11R-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo(5,6)cyclohepta(1,2-b)pyridine-11-yl)-1-piperidinyl)-2-oxoethyl)-;

MeSH Related Number : 193275-84-2;

Registry Number MeSH : 193275-84-2;

Is substance : O;

UNII : IOW153004F;

Details


Main resources

You can consult :


https://www.has-sante.fr/jcms/p_3424350/fr/zokinvy-lonafarnib-maladie-rare
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
adolescent
progeria
orphan drug production
progeria
Laminopathies
Laminopathies
genetic testing
Product containing only lonafarnib in oral dose form (medicinal product form)
evaluation of the transparency committee
zokinvy
rare diseases
lonafarnib

---
https://www.has-sante.fr/jcms/p_3455546/fr/zokinvy-lonafarnib-syndrome-de-hutchinson-gilford
2023
false
false
false
France
French
treatment outcome
insurance, health, reimbursement
progeria
lonafarnib
lonafarnib
evaluation of the transparency committee
zokinvy
Laminopathies
administration, oral

---
https://ansm.sante.fr/tableau-acces-derogatoire/lonafarnib-zokinvy
2023
false
false
false
France
French
administration, oral
lonafarnib
lonafarnib
drug information
progeria
Laminopathies
Laminopathy with premature aging (disorder)
Laminopathy with premature aging (disorder)
mutation
Lamin A/C gene mutation
zinc metallopeptidase STE24

---
https://www.has-sante.fr/jcms/p_3368156/fr/zokinvy-lonafarnib-syndrome-de-hutchinson-gilford
2022
false
false
false
France
progeria
treatment outcome
insurance, health, reimbursement
infant
child
Laminopathies
Laminopathies
mutation
LMNA Gene
zinc metallopeptidase STE24
guidelines for drug use
administration, oral
continuity of patient care
evaluation of the transparency committee
zokinvy
lonafarnib

---
https://www.ema.europa.eu/en/medicines/human/EPAR/zokinvy
2022
false
false
false
Netherlands
French
English
lonafarnib
lonafarnib
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
orphan drug production
infant
child
progeria
drug approval
europe
lonafarnib
Laminopathies
administration, oral
Product containing precisely lonafarnib 50 milligram/1 each conventional release oral capsule (clinical drug)
Product containing precisely lonafarnib 75 milligram/1 each conventional release oral capsule (clinical drug)
product surveillance, postmarketing
Laminopathies
mutation
zinc metallopeptidase STE24
LMNA Gene
adolescent
adult
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical

---
Nous contacter.
18/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.